VARI researchers find ways to reverse resistance to sunitinib: Patients with ccRCC sh

[News]

Van Andel Research Institute researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.

More... (http://www.news-medical.net/news/20100219/VARI-researchers-find-ways-to-reverse-resistance-to-sunitinib-Patients-with-ccRCC-show-positive-response.aspx)